Short Answer

Both the model and the market overwhelmingly agree that marijuana will be rescheduled before Jan 20, 2029, with only minor residual uncertainty.

1. Market Behavior & Drivers

This prediction market has exhibited a sideways trend with a slight downward drift, trading within an extremely narrow range of 0.9% to 1.4%. The price started at 1.4% and has since settled near its all-time low of 0.9%, which is acting as a key support level, while 1.4% serves as resistance. Despite a total volume of over 24,000 contracts, the sample data points suggest trading may be infrequent, indicating a general lack of new information or conviction to move the price significantly. The market's stability at this very low probability suggests a strong consensus among traders.
The price action indicates that the market does not view the recent administration action as sufficient to resolve this market as "YES". Even after the administration officially reclassified certain FDA-approved and state-licensed medical marijuana products to Schedule III, the market price remained near its lows. This lack of a positive price response suggests traders interpret the market's resolution criteria as requiring a broader, more comprehensive rescheduling of all marijuana, not just specific products. The persistent low probability implies that traders believe such a comprehensive change is highly unlikely.
Overall, the chart reflects a deeply pessimistic market sentiment regarding the prospect of a full marijuana rescheduling. The price has been static and unresponsive to recent news that might otherwise seem positive. This suggests traders have priced in the partial reclassification as a non-event for the purposes of this specific market and see no catalysts on the horizon that would lead to a "YES" resolution. The low price and sideways movement indicate a stable belief that the conditions for this market will not be met.
  • Trump administration took concrete steps towards broader marijuana rescheduling.
  • An administrative hearing to evaluate rescheduling is scheduled for mid-2026.
  • Finalization of broader rescheduling by July 15, 2026, is extremely unlikely.
  • Finalization by year-end 2026 appears highly improbable, given typical timelines.
  • Internal opposition and litigation may significantly delay the rescheduling process.
  • The Department of Justice finalized a partial rescheduling rule in April 2026.

Who Wins and Why

Outcome Market Model Why
Before 2027 27.0% 20.8% Finalizing rescheduling before 2027 is highly improbable due to the July 2026 hearing and typical 18-36 month process.
Before 2028 70.0% 72.2% The Trump administration has taken concrete steps, including an executive order, to expedite rescheduling.
Before Jan 20, 2029 81.0% 82.4% The Trump administration has taken concrete steps, including an executive order, to expedite rescheduling.

Current Context

The administration recently reclassified certain marijuana products to Schedule III. As of April 23, 2026, the Trump administration officially reclassified FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act [1][2][3][4]. This action altered the federal classification for specific cannabis-related items.
Broader marijuana rescheduling is progressing, driven by an executive order. The larger initiative to reschedule all marijuana from Schedule I to Schedule III remains an ongoing process, with the Drug Enforcement Administration (DEA) scheduling an administrative hearing to commence on June 29, 2026, to evaluate this proposed change [5][1][6][7]. This expedited rulemaking process for rescheduling marijuana to Schedule III was directed by President Trump's Executive Order 14370, issued on December 18, 2025, which mandated the Attorney General to complete the process as expeditiously as possible [1][6][7][8].
Sources (8)
  1. 1Justice Department Places FDA-Approved Marijuana Products and...justice.gov
  2. 2Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirementsjustice.gov
  3. 3Federal Register, Volume 91 Issue 81 (Tuesday, April 28, 2026)govinfo.gov
  4. 4Trump administration reclassifies cannabis as less dangerous - BBC Newsbbc.co.uk
  5. 5Federal Register, Volume 91 Issue 81 (Tuesday, April 28, 2026)govinfo.gov
  6. 6Schedules of Controlled Substances: Rescheduling of Marijuana; Notice of hearing on proposed rulemakingjustice.gov
  7. 7Schedules of Controlled Substances: Rescheduling of Marijuana | 91 FR 22777thefederalregister.org
  8. 8Increasing Medical Marijuana and Cannabidiol Researchwhitehouse.gov

2. Price Chart

Historical Price (Probability)

Outcome probability
Date

3. Market Data

Contract Snapshot

The market resolves to "Yes" if marijuana is legally rescheduled from Schedule I to a lower drug schedule or entirely unscheduled under the Controlled Substances Act before January 1, 2028. It resolves to "No" if this condition is not met by the deadline, and only reclassifying specific cannabis derivatives or cannabinoids without affecting marijuana as a whole does not qualify. For a "Yes" resolution, the rescheduling must have taken legal effect, not merely been announced or published in the Federal Register.

Available Contracts

Market options and current pricing

Outcome bucket Yes (price) No (price) Last trade probability
Before 2027 $0.29 $0.73 27%
Before 2028 $0.69 $0.33 70%
Before Jan 20, 2029 $0.80 $0.24 81%

Market Discussion

The market indicates a strong probability (81%) of marijuana being rescheduled by January 2029, though the likelihood drops to 27% for rescheduling by 2027. A key point of discussion and confusion among traders revolves around the specific definition of "rescheduled" under the market rules; some incorrectly believe it has already occurred, prompting clarifications that the entire substance, not just derivatives or medical cannabis, must be removed from Schedule I. Arguments for "Yes" are often rooted in political considerations or perceived government loosening of restrictions, while "No" arguments focus on strict interpretation of the rules and potential legal challenges to rescheduling efforts.

4. Trust Index

Octagon Trust Index Kalshi 77 Good

Largest single print on KXMJSCHEDULE-29 carried 56% of its $3,543 tape (print is 3d old)

Integrity risk· Large trades

How it adds up
Integrity80% of score81Good
Trade quality20% of score63Caution

Includes the cost to trade: a $10,000 order can't be filled here because the order book is too thin.

Trust score77Good

Weighted blend with hard caps — a critically weak safety pillar, or a severe trading anomaly, caps the total regardless of the rest. Full methodology · About the Trust Index

Trust profile
Integrity4 screens run · 6 don't apply
Market integrity
74Good

Outcome is hard to influence

Large tradesTrade signals · medium confidence

Largest single print on KXMJSCHEDULE-29 carried 56% of its $3,543 tape (print is 3d old)

Screened clean
Thin-volume movesMoves carried volume Clear
Size patternsNo distribution read Clear
2 screens not run
Outcome control · doesn't apply to this market type
Thin-leg conviction · doesn't apply to this market type
Info fairness
80Good

Structural prior — no screens apply

No suspicious activity on any screen

Screened clean
Information exposureNo concentrated group can know the outcome materially early. Clear
4 screens not run
Move vs. catalyst · doesn't apply to this market type
Longshot repricing · doesn't apply to this market type
Pre-broadcast certainty · doesn't apply to this market type
Cross-venue timing · doesn't apply to this market type
Resolution quality
92Strong

Resolution mechanism is dependable

No suspicious activity on any screen

Resolution rules read: Clear

Liquidity
80Deep

Size fills near the screen price

3 contracts · worst first

Before 202776
Tradeable · low confidence

Light recent trading — size may not fill near the screen price.

Before Jan 20, 202983
Deep · medium confidence

Typical bar range 1.3% of price over 4 traded bars

24h traded notional $2,060 · 24h
Before 202884
Deep · high confidence

Typical bar range 1.3% of price over 5 traded bars

24h traded notional $2,589 · 24h
Move quality
89Confirmed

Moves came with real volume

3 contracts · worst first

Before Jan 20, 202989
Confirmed · medium confidence

Volume confirms the move over 24h

Before 2028—
No significant move (24h)

Price was stable over the last 24 hours.

Before 2027—
No significant move (6h)

Price was stable over the last 6 hours.

Rule clarity
100Clear

Counts toward Resolution quality, not here

3 contracts · worst first

Before Jan 20, 2029100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Before 2028100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Before 2027100
Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Trade quality
63Caution

Order book is thin

Tradable, but expect execution cost beyond small sizes.

Outcome quality 81 (notional-weighted across 3 scored legs)

$100 order: 2.1c slippage (~9% of a 24c contract)

$1,000 order: 2.9c slippage (~12% of a 24c contract)

$10,000 order: book too thin to fill

Before Jan 20, 202985Market scoreLiquidity83Move quality89Rule clarity100
Why 85
Liquidity
83 · Deep · medium confidence

Typical bar range 1.3% of price over 4 traded bars

24h traded notional $2,060 · 24h
Move quality
89 · Confirmed · medium confidence

Volume confirms the move over 24h

Rule clarity
100 · Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Before 202884Market scoreLiquidity84Move quality–Rule clarity100
Why 84
Liquidity
84 · Deep · high confidence

Typical bar range 1.3% of price over 5 traded bars

24h traded notional $2,589 · 24h
Move quality
No significant move (24h)

Price was stable over the last 24 hours.

Rule clarity
100 · Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear
Before 202776Market scoreLiquidity76Move quality–Rule clarity100
Why 76
Liquidity
76 · Tradeable · low confidence

Light recent trading — size may not fill near the screen price.

Move quality
No significant move (6h)

Price was stable over the last 6 hours.

Rule clarity
100 · Clear · high confidence

All checks pass

objective outcome · Clearofficial source · Cleartime boundary · Clear

underwriting_v1.4 · computed Sep 23, 2026

5. What are the key arguments and procedural hurdles anticipated in the DEA's administrative hearing starting June 29, 2026?

Hearing Start DateJune 29, 2026 [1][2][3][4][5][6]
Hearing End DateJuly 15, 2026 [1][2][3][4][5][6]
Executive Order DateDecember 2025 [3][7]
The DEA’s administrative hearing on marijuana rescheduling begins June 29, 2026. This hearing, scheduled to conclude by July 15, 2026, aims to address crucial arguments regarding data focus for rescheduling and navigate procedural challenges concerning participant selection and legal compliance [1][2][3][4][5][6]. The proceeding was initiated following President Trump's Executive Order 14370 in December 2025, which directed the Attorney General to expedite the rescheduling rulemaking process. This directive led the DEA to terminate previous stalled hearing proceedings [3][7].
Central arguments debate data scope and procedural fairness challenges. A key debate involves whether to concentrate solely on medical and pharmacological data or to also consider the practical, commercial realities of the current state-legal marijuana industry [4][5]. Advocates for reform generally push for descheduling rather than merely rescheduling marijuana to Schedule III, while prohibitionist groups remain opposed to any form of rescheduling [4][5]. Procedural hurdles anticipated include the selection of hearing participants and mitigating potential litigation concerning bias or conflicts of interest. The DEA is also tasked with balancing administrative efficiency with full adherence to the Administrative Procedure Act and the Controlled Substances Act [4][5][6].
Sources (7)
  1. 1Schedules of Controlled Substances: Rescheduling of Marijuana; Notice of hearing on proposed rulemakingjustice.gov
  2. 2Federal Register, Volume 91 Issue 81 (Tuesday, April 28, 2026)govinfo.gov
  3. 3Proposed Rulesgovinfo.gov
  4. 4DEA Hearing Roster Will Define the Cannabis Rescheduling Narrative in 2026mgmagazine.com
  5. 5Marijuana Legalization Supporters And Opponents File Notices To Participate In DEA Hearing On Rescheduling Next Month - Marijuana Momentmarijuanamoment.net
  6. 6Cannabis Rescheduling: Why “Expedite” Is Political, Not Legal | Harris Beach Murthaharrisbeachmurtha.com
  7. 7Schedules of Controlled Substances: Rescheduling of Marijuana; Withdrawal | 91 FR 22778thefederalregister.org

6. What evidence points to significant opposition from within the DEA or other federal agencies that could delay rescheduling past July 2026?

Administrative Hearing StartJune 29, 2026 [1][2][3]
Administrative Hearing EndJuly 24, 2026 [1][2][3]
Final Broader Rescheduling ExpectedPast July 2026 [4][5]
Internal DEA opposition and a lengthy hearing timeline impede rescheduling efforts. The rescheduling process faces significant internal opposition and procedural friction within the DEA, including allegations of improper communications with anti-rescheduling parties and stalled administrative appeals [6][7][8]. A critical administrative hearing for the proposed rescheduling is scheduled to begin on June 29, 2026, and conclude by July 24, 2026 [1][2][3]. Given the extensive requirements for this hearing, such as evidence submission, cross-examination, and a subsequent briefing period, the finalization of rescheduling before July 2026 appears highly improbable [4][5].
External legal and legislative actions may further delay rescheduling past 2026. Beyond the DEA's internal challenges and the administrative hearing's schedule, external factors are expected to extend broader rescheduling beyond July 2026 [4][5]. These factors include potential federal litigation, specifically a motion to stay an April 2026 order related to certain marijuana products, and possible Congressional action under the Congressional Review Act [4][5]. Furthermore, prediction markets indicate widespread skepticism regarding a prompt rescheduling outcome [9].
Sources (9)
  1. 1Federal Register, Volume 91 Issue 81 (Tuesday, April 28, 2026)govinfo.gov
  2. 2Schedules of Controlled Substances: Rescheduling of Marijuana; Notice of hearing on proposed rulemakingjustice.gov
  3. 3Justice Department Places FDA-Approved Marijuana Products and...justice.gov
  4. 4Anti-Rescheduling Parties Ask Court to Stay Schedule III Cannabis Ordercannabisbusinesstimes.com
  5. 5After Schedule III: What the June 2026 Hearing Could Change – HealthDataConsortium.orghealthdataconsortium.org
  6. 6Marijuana Rescheduling Blocked By Opposition 'From Within' DEA, Biden's Drug Czar Says - Marijuana Momentmarijuanamoment.net
  7. 7New Evidence Shows DEA Opposes Marijuana Rescheduling And Should Be Removed From Hearings, Cannabis Groups Say - Marijuana Momentmarijuanamoment.net
  8. 8Marijuana Rescheduling Appeal Process 'Remains Pending' Despite Trump's Executive Order, DEA Says In New Filing - Marijuana Momentmarijuanamoment.net
  9. 9Trump moves to reclassify medical marijuana, impacting prediction marketscryptobriefing.com

7. How do the legal and economic consequences of the April 2026 partial rescheduling differ from those of a full move to Schedule III for all marijuana?

Rescheduling effective dateApril 23, 2026 [1][2][3]
Products affected by reschedulingFDA-approved and state medical marijuana products [1][2][3]
Tax relief for medical operatorsPotential elimination of IRC Section 280E disallowance [1][4][5]
Partial rescheduling offers tax relief for medical marijuana, not adult-use. The April 2026 partial rescheduling, effective April 23, 2026, reclassifies only FDA-approved marijuana products and those regulated by state medical marijuana licenses to Schedule III, leaving adult-use marijuana in Schedule I [1][2][3]. The primary economic consequence is the potential elimination of Internal Revenue Code Section 280E's tax disallowance for compliant medical marijuana operators. This change enables these businesses to deduct ordinary and necessary business expenses, a benefit not extended to adult-use marijuana operators [1][4][5].
Legal complexities arise, impacting dual-licensed operators and future rescheduling. This partial rescheduling introduces new legal challenges, particularly for dual-licensed operators who must segment their revenue between medical and adult-use operations to qualify for 280E relief [2][3][6]. Adult-use activities continue to be subject to full Schedule I criminal and regulatory prohibitions [2][3][6]. Following the announcement, prediction markets indicated a sharp decrease in the short-term probability of full plant rescheduling. This is because the move established an extended administrative hearing process for broader rescheduling, which is set to begin on June 29, 2026 [3][7].
Sources (7)
  1. 1Cannabis Rescheduled to Schedule III: A Historic Shift in Federal Drug Policy - Frier Levitt Cannabis Rescheduled to Schedule III: What It Means for Tax, Banking, and Researchfrierlevitt.com
  2. 2DOJ’s April 2026 Cannabis Order: What It Does And What It Does Not Do - - United Statesmondaq.com
  3. 3Marijuana's Move to Schedule III: What Changes, What Doesn'tnolo.com
  4. 4280E Tax Marijuana Rescheduling: Critical 2026 DOJ Impact Guidehighrock.co
  5. 5Medical First, Recreational Later? DOJ’s Cannabis Order And The Stakes Ahead | Benesch Lawbeneschlaw.com
  6. 6Department of Justice Eases Control of Medical Marijuana - EveryCRSReport.comeverycrsreport.com
  7. 7Will Marijuana Be Rescheduled? Kalshi Odds & Analysisactionnetwork.com

8. What further actions could the Trump administration or the Attorney General take before July 2026 to accelerate the final rescheduling rule?

Roster Finalization DueJune 22, 2026 [1]
DEA Hearing StartJune 29, 2026 [2][3][4][1]
Interim Rescheduling OrderApril 28, 2026 [4][1][5]
Finalizing the hearing roster is the critical immediate action needed for rescheduling. The most pressing remaining action to accelerate the final rescheduling rule for marijuana before July 2026 is the Acting Attorney General's finalization of the hearing participant roster. This crucial step, expected by June 22, 2026, will define the scope and potential challenges of the upcoming hearing process [1].
The administration has already taken steps to advance marijuana rescheduling. The Trump administration has significantly expedited the rescheduling process through Executive Order 14370, issued on December 18, 2025. These actions included terminating a prior stalled hearing process and issuing an order on April 28, 2026, which immediately reclassified FDA-approved marijuana products and state-licensed medical marijuana into Schedule III [4][1][5]. However, the legal framework mandates the completion of a full administrative hearing before a final rule for broader rescheduling can be formally enacted [6]. A new administrative hearing concerning the proposed rescheduling of marijuana is scheduled to commence by the DEA on June 29, 2026, with proceedings expected to conclude no later than July 15, 2026 [2][3][4][1].
Beyond roster finalization, few further actions can accelerate the rule. While the Attorney General possesses broad authority under 21 U.S.C. 811 to direct the scheduling process [6], the available information does not specify further actions that could be taken by the administration or Attorney General before July 2026 to accelerate the final rescheduling rule beyond finalizing the hearing participant roster [6].
Sources (6)
  1. 1DEA Hearing Roster Will Define the Cannabis Rescheduling Narrative in 2026mgmagazine.com
  2. 2Federal Register, Volume 91 Issue 81 (Tuesday, April 28, 2026)govinfo.gov
  3. 3Schedules of Controlled Substances: Rescheduling of Marijuana; Notice of hearing on proposed rulemakingjustice.gov
  4. 4Justice Department Places FDA-Approved Marijuana Products and...justice.gov
  5. 5Office of Public Affairs | Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Subject to a Qualifying State-issued License in Schedule III, Strengthening Medical Research While Maintaining Strict Federal Controls | United States Department of Justicejustice.gov
  6. 6U.S.C. Title 21 - FOOD AND DRUGSgovinfo.gov

9. Based on historical precedents, what is the typical timeframe for the DEA to finalize a rescheduling rule after an administrative hearing begins?

Formal Hearing Start DateJune 29, 2026 [1][2][3]
Formal Hearing End DateNo later than July 15, 2026 [1][2][3]
Historical Post-Hearing Timeline18-36 months (DEA administrative hearing to final rule) [4][5][6]
A formal hearing on marijuana rescheduling is scheduled for mid-2026. The administrative hearing for the proposed rescheduling of marijuana is set to commence on June 29, 2026, and conclude by July 15, 2026 [1][2][3]. This process is mandated by President Trump's Executive Order 14370, issued on December 18, 2025, which requires the Attorney General to complete the rescheduling [1][2][3].
Historically, DEA rule finalization takes 18 to 36 months. The timeframe from a DEA administrative hearing to the issuance of a final rule has typically been unpredictable, often ranging from 18 to 36 months [4][5][6]. Delays are frequently observed after the conclusion of the hearing, particularly during the Administrator's review of the Administrative Law Judge's recommended decision [4][5][6].
Sources (6)
  1. 1Federal Register, Volume 91 Issue 81 (Tuesday, April 28, 2026)govinfo.gov
  2. 2Schedules of Controlled Substances: Rescheduling of Marijuana; Notice of hearing on proposed rulemakingjustice.gov
  3. 3Schedules of Controlled Substances: Rescheduling of Marijuana | 91 FR 22777thefederalregister.org
  4. 4DEA Proposes Significant Changes to Administrative Hearings | DEA Chroniclesdeachronicles.com
  5. 5What To Do When You Receive a DEA Order to Show Cause - iPharmgipharmag.com
  6. 6DEA Rescheduling Process: How Federal Cannabis Classification Works — ongoing CannIntel coverage · CannIntelcannintel.com

10. What Could Change the Odds

Key Catalysts

The Department of Justice finalized a rule as of April 23, 2026, placing FDA-approved products containing marijuana and products regulated by a state-issued medical marijuana license into Schedule III [1][2]. Following President Trump's December 18, 2025, Executive Order (E.O. 14370), the DEA initiated a new expedited administrative hearing process regarding the rescheduling of marijuana from Schedule I to Schedule III, scheduled to commence on June 29, 2026, and conclude no later than July 15, 2026 [1][3][4][5].
Prediction markets currently show high sentiment (around 77-83%) that full marijuana rescheduling to Schedule III will occur before January 20, 2029 [6][7][8]. However, near-term confidence (before July 2026) is low (approximately 10-22%) due to the anticipated length of the administrative process [6][7][8]. Market catalysts include the potential elimination of the punitive 280E tax provision, improved institutional capital access, and federal regulatory harmonization, which analysts expect will drive a major industry re-rating upon formal implementation of Schedule III status [9][10][11][12][13].

Key Dates & Catalysts

  • Expiration: July 08, 2026
  • Closes: January 20, 2029
Sources (13)
  1. 1Office of Public Affairs | Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Subject to a Qualifying State-issued License in Schedule III, Strengthening Medical Research While Maintaining Strict Federal Controls | United States Department of Justicejustice.gov
  2. 2Federal Register, Volume 91 Issue 81 (Tuesday, April 28, 2026)govinfo.gov
  3. 3Federal Register, Volume 91 Issue 81 (Tuesday, April 28, 2026)govinfo.gov
  4. 4Schedules of Controlled Substances: Rescheduling of Marijuana; Notice of hearing on proposed rulemakingjustice.gov
  5. 5Schedules of Controlled Substances: Rescheduling of Marijuana | 91 FR 22777thefederalregister.org
  6. 6Will marijuana be rescheduled? | Politics Prediction Markets | Solflaresolflare.com
  7. 7Will Marijuana be Rescheduled?next.io
  8. 8Trump moves to reclassify medical marijuana, impacting prediction marketscryptobriefing.com
  9. 9Legal Cannabis Market Growth Analysis - Size and Forecast 2026-2030 | Technaviotechnavio.com
  10. 10Cannabis Industry Outlook 2026: $40.5B Sales Forecast & 6 Stocks to Watch | Budpediabudpedia.com
  11. 11The State of Cannabis in 2026: Industry Trends, New Markets, and What to Watch | Green Rushgreenrushnews.com
  12. 12Marijuana Rescheduling and 280E Removal: The 2026 Catalyst for Cannabis Equity Re-Ratingainvest.com
  13. 13Cannabis at an Inflexion Point - by Business of Cannabistoddharrison.substack.com

12. Related News

-27.4pp
Last updated: June 14, 2026, 22:33 UTC

Marijuana Rescheduling Market Pushes Out Timeline After DOJ Action

Probabilities for a near-term, comprehensive federal rescheduling of marijuana fell sharply on Thursday, April 23, 2026, after the Department of Justice (DOJ) announced a final order that reclassified...
+19.0pp
Last updated: June 14, 2026, 22:33 UTC

Marijuana Rescheduling Timeline Compresses Sharply on DOJ News

Prediction markets tracking the federal rescheduling of marijuana saw a sharp, positive repricing on Wednesday, April 22, 2026, as all contracts moved toward a significantly accelerated timeline. The ...